Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.54
- Piotroski Score 4.00
- Grade Overweight
- Symbol (ALVO)
- Company Alvotech
- Price $12.67
- Changes Percentage (-0.63%)
- Change -$0.08
- Day Low $12.63
- Day High $12.84
- Year High $18.00
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $22.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.08
- Trailing P/E Ratio -6.75
- Forward P/E Ratio -6.75
- P/E Growth -6.75
- Net Income $-551,731,000
Income Statement
Quarterly
Annual
Latest News of ALVO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ChatGPT releases a search engine, an opening salvo in a brewing war with Google for dominance of the AI-powered internet
OpenAI's new ChatGPT Search challenges Google's dominance in the search engine market by providing real-time information sourced from reputable sources. The tool aims to simplify online searches with ...
By Yahoo! Finance | 5 days ago -
Resentencing for Lee Malvo postponed in Maryland after Virginia says he can't attend in person
A Maryland judge indefinitely postponed a resentencing hearing for sniper Lee Boyd Malvo after Virginia refused to let him attend. Malvo and John Allen Muhammad terrorized the D.C. area in 2002. Malvo...
By AP NEWS | 1 month ago -
An Intrinsic Calculation For Valvoline Inc. (NYSE:VVV) Suggests It's 27% Undervalued
The analyst price target for Valvoline Inc. (NYSE: VVV) is 14% lower than the estimated fair value. A Discounted Cash Flow (DCF) model is used to assess the investment attractiveness, showing the stoc...
By Yahoo! Finance | 1 month ago
